Loading clinical trials...
Loading clinical trials...
The Hemodynamics Effect of Levcromakalim After Glibenclamide Administration Assessed by High Resolution MRA Technique in a Randomized, Double-blind, Cross-over and Placebo-controlled Study With Healthy Volunteers.
To investigate the effect of levcromakalim/placebo infusion on cranial arteries after glibenclamide administration.
15 healthy participants will randomly be allocated to receive levcromakalim or placebo on to different days before and after oral glibenclamide administration. The aim of the study is to investigate the effect of levcromakalim/placebo infusion on cranial arteries before and after glibenclamide administration. Repeated magnetic resonance angiography (MRA) measurements covering the middle meningeal artery (MMA), superficial temporal artery (STA) and middle cerebral artery (MCA) before and after glibenclamide administration and levcromakalim/placebo infusion.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
Yes
Danish headache center
Glostrup Municipality, Copenhagen, Denmark
Mohammad Al-Mahdi Al-Karagholi
København S, Danmark, Denmark
Start Date
April 1, 2019
Primary Completion Date
August 30, 2023
Completion Date
August 30, 2023
Last Updated
July 7, 2022
15
ESTIMATED participants
Levcromakalim
DRUG
Saline
DRUG
Lead Sponsor
Danish Headache Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07477236